共 50 条
- [21] Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (10) : 1101 - 1107Wetten, AaronJones, David Emrys JeffreysDyson, Jessica Katharine
- [22] ALKALINE PHOSPHATASE CHANGES WITH SELADELPAR ACROSS SUBGROUPS OF PRIMARY BILIARY CHOLANGITIS PATIENTS IN THE RESPONSE TRIALHEPATOLOGY, 2024, 80 : S1822 - S1823Kowdley, KrisYimam, KidistKumar, SonalMena, EdwardBonder, AlanReddy, K. GauthamCorpechot, ChristopheCarroll, SusheelaYang, KeCrittenden, DariaMcWherter, Charles
- [23] Pharmacokinetics and pharmacodynamics of seladelpar, a potent and selective PPAR-delta, in patients with primary biliary cholangitisJOURNAL OF HEPATOLOGY, 2018, 68 : S235 - S235Boudes, P.Michael, G.Bowlus, C.Hirschfield, G.Jones, D.Odin, J.Sheridan, D.Gitlin, N.Harrison, S.Hassanein, T.Levy, C.Shiffman, M.Thorburn, D.Thuluvath, P. J.Vierling, J.Choi, Y. -J.Varga, M.Steinberg, A.Mcwherter, C.Martin, R.
- [24] Alkaline Phosphatase Changes With Seladelpar Across Subgroups Of Primary Biliary Cholangitis Patients In The Response TrialDIGESTIVE AND LIVER DISEASE, 2025, 57Kowdley, K.Yimam, K.Kumar, S.Mena, E.Bonder, A.Reddy, K. GauthamCorpechot, C.Carroll, S.Frigerio, F.Yang, K.Crittenden, D. B.Mcwherter, C.
- [25] TREATMENT WITH SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AND PRIOR EXPERIENCE WITH OBETICHOLIC ACID OR FIBRATESGASTROENTEROLOGY, 2022, 162 (07) : S1192 - S1193Gulamhusein, AliyaNeff, GuyGoel, AparnaMayo, Marlyn J.Stanca, Carmen M.Bowlus, Christopher L.Forman, LisaInvernizzi, PietroNevens, FrederikZigmond, EhudZuckerman, EliYang, KeChoi, Yun-JungSteinberg, AlexandraMcwherter, Charles A.Kowdley, Kris V.
- [26] Safety and Efficacy of Seladelpar in Treatment of Patients With Primary Biliary Cholangitis: A Systematic Review and Meta-AnalysisAMERICAN JOURNAL OF THERAPEUTICS, 2025, 32 (02) : e194 - e197Raja, AdarshAhmed, MuhammadRaja, SandeshRahman, Hafsah Alim UrKumar, MukeshAsghar, Muhammad SohaibKumar, Sumet
- [27] Treatment with seladelpar in patients with primary biliary cholangitis (PBC) and prior experience with obeticholic acid (OCA) or fibratesJOURNAL OF HEPATOLOGY, 2021, 75 : S690 - S691Gulamhusein, AliyaNeff, GuyGoel, AparnaMayo, Marlyn J.Stanca, CarmenBowlus, ChristopherForman, LisaInvernizzi, PietroNevens, FrederikZigmond, EhudZuckerman, EliYang, KeChoi, Yun-JungSteinberg, AlexandraMcWherter, CharlesKowdley, Kris
- [28] EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH COMPENSATED CIRRHOSIS AND EVIDENCE OF PORTAL HYPERTENSION DUE TO PRIMARY BILIARY CHOLANGITIS (PBC)HEPATOLOGY, 2021, 74 : 762A - 763ALevy, CynthiaOdin, JosephNeff, Guy W.Trivedi, PalakGheorghe, Liliana-SimonaBowlus, Christopher L.Vierling, John M.Gulamhusein, Aliya F.Jeong, Sook-HyangXu, EmilyYang, KeChoi, Yun-JungWatkins, ElaineMcWherter, Charles
- [29] Primary Biliary Cholangitis and Primary Sclerosing CholangitisAMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 (10): : 1593 - 1605Yokoda, Raquel T.Carey, Elizabeth J.
- [30] Treatment of patients with primary biliary cholangitis with seladelpar for 52 weeks improves predicted transplant-free survivalJOURNAL OF HEPATOLOGY, 2019, 70 (01) : E403 - E404Perez, Carla Fiorella MurilloBoudes, PolSteinberg, AlexandraVarga, MonikaChoi, Yun-JungJanssen, HarryGulamhusein, AliyaHirschfield, GideonHansen, Bettina